Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Hope and Challenges for Personalized Medicine Highlighted
March 22, 2010
- Sato to Launch OTC Version of Troxipide
March 22, 2010
- Roche Suspends Development of Ocrelizumab Due to Adverse Reactions
March 22, 2010
- J-CLEAR Created for Objective Assessment of Data from Clinical Studies
March 22, 2010
- Gov't Should More Strongly Support Pharma Industry: Dr Teshirogi
March 22, 2010
- Merck to More Actively Tie Up with Others in Early Development Stage
March 22, 2010
- Eli Lilly Japan's Sales Up 19% in 2009
March 22, 2010
- Torii to Develop Sublingual Desensitization Therapy for Pollinosis
March 22, 2010
- Mediceo to Cut Costs Taking Advantage of ALCs
March 22, 2010
- Takara Bio Ties Up with Univ. of Pennsylvania for HIV Gene Therapy
March 22, 2010
- Morimoto Proposes Shared Manufacturing Site in Shanghai
March 22, 2010
- Pfizer Discontinues PIII Study of Figitumumab for Advanced NSCLC
March 22, 2010
- Will the Era of DI Pharmacists Arrive?
March 22, 2010
- VEGF Trap-Eye Improved Visual Acuity in Patients with DME: Bayer
March 22, 2010
- Kyowa Kirin, Solasia Sign License Agreement for Sancuso in Asia
March 15, 2010
- Eli Lilly, Merck, Pfizer to Jointly Create Cancer DB in Asia
March 15, 2010
- NanoCarrier to Obtain Process Patent on NC-4016 in the US
March 15, 2010
- SymBio Begins PII Trial of Bendamustine for Aggressive NHL
March 15, 2010
- Tsumura to Procure Raw Materials for Kampo Medicines in Laos
March 15, 2010
- JCPM to Provide e-Learning Programs for Clinical Trials
March 15, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…